Management strategies for cytomegalovirus infection and disease in solid organ transplant recipients

Research output: Contribution to journalReview article

40 Scopus citations


Cytomegalovirus is the most common viral pathogen that affects solid organ transplant recipients. It directly causes fever, myelosuppression, and tissue-invasive disease, and indirectly, it negatively impacts allograft and patient survival. Nucleic acid amplification testing is the preferred method to confirm the diagnosis of CMV infection. Prevention of CMV disease using antiviral prophylaxis or preemptive therapy is critical in the management of transplant patients. Intravenous ganciclovir and oral valganciclovir are the first line drugs for antiviral treatment. This article provides a comprehensive review of the current epidemiology, diagnosis, prevention and treatment of CMV infection in solid organ transplant recipients.

Original languageEnglish (US)
Pages (from-to)317-342
Number of pages26
JournalInfectious Disease Clinics of North America
Issue number2
StatePublished - Jun 1 2013



  • Allograft rejection
  • Cytomegalovirus
  • Graft failure
  • Nucleic acid testing
  • Polymerase chain reaction
  • Valganciclovir
  • Viral load

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases

Cite this